Aditya Birla Capital Regulatory Approval

Aditya Birla Capital Debt & Borrowing

Aditya Birla Capital confirms full utilization of NCD and sub-debt issue proceeds for Q3 FY27 under Reg 52(7). No deviation from intended use was reported across 12 listed tranches.

Aditya Birla Capital Other Announcement

Aditya Birla Capital filed a quarterly Monitoring Agency Report confirming no deviation in utilizing its ₹4,000 Crore Preferential Issue proceeds. The filing covers the quarter ended 30 September 2026.

Aditya Birla Capital Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue ₹16,545 Cr (+31% y-o-y) and PAT ₹1,288 Cr (+38% y-o-y). Lending portfolio ₹2,33,930 Cr (+32%). Strategy centres on AI-led underwriting and omnichannel distribution.

Aditya Birla Capital Q2 FY27 Results: Net Profit ₹1,353 Cr, Up 40.9% YoY

Aditya Birla Capital Ltd reported revenue from operations of ₹14,003 Cr (+32.2% YoY) and net profit of ₹1,353 Cr (+40.9% YoY) for Q2 FY27.

Key figure

Net profit ₹1,353 Cr · +40.9% YoY

Aditya Birla Capital Employee Stock Options

Aditya Birla Capital allotted 24,884 equity shares under its ESOP/RSU/PSU schemes on October 23, 2026. Paid-up capital increased to 27,38,00,66,370 shares of ₹10 each.

Aditya Birla Capital Debt & Borrowing

Aditya Birla Capital Limited fixed record dates for interest payments on various NCD series due in December 2026.

Vedavaag Systems Regulatory Approval

Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.

Hikal Regulatory Approval

Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.

Sun Pharmaceutical Industries Regulatory Approval

Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.

RNFI Services Regulatory Approval

RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.